Innovation Matrix is a four-dimensional endeavour which extends
into the realms of the known and the unknown.
Creativity in the known realm builds on existing knowledge and
can result in two types of innovation:
INCREMENTAL and EVOLUTIONARY. Creativity that challenges unknown
boundaries and creates new knowledge is
EXPERIMENTAL and TRANSFORMATIONAL in its impact. A portfolio
that covers all four spheres enables Biocon to
sustain innovation in the short, medium and long term. (source:
company website).
8/9/2019 Biocon Strategy
3/4
Biocons biosimilar insulin, an outcome of incrementalinnovation,
is one of the worlds most affordable therapiesfor insulin dependent
diabetes.
Biocon is the first company to have successfully
commercialized the large-scale manufacture of humaninsulin,
using a proprietary methylotrophic yeast basedtechnology. This
resulted in the launch of our insulin brand,Insugen, in 2004,
representing our entry into the brandedformulations market.
Biocon also pursuing a path of breakthrough innovationthrough
phase III human clinical trials to develop theworlds first Oral
Insulin. Biocon is thus rapidly movingtowards commercializing novel
biologics with a "Made inIndia" label (source: company annual
report 2010)
8/9/2019 Biocon Strategy
4/4
In this fiscal, Biocon Diabetology grew 24% supportedby strong
sales from brand INSUGEN. As per ORGestimates, Biocon are ranked
15th in the coveredmarket and 18th in the overall diabetic
market.
Biocons India strategy is reaping rich reward ascontinue to
focus on leadership in key therapies withinthe domestic branded
formulations segment. Bybuilding large brands, entering more
therapeutic areasand increasing the number of new introductions
each
year, Biocons healthcare divisions are deliveringaffordable
innovation to millions of patients across thecountry. (source:
company annual report 2010)
